Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation.
about
The global distribution of yellow fever and dengueThe dengue virusesChemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in MosquitoesConstruction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for miceDengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeysMonkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challengeDengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activityDengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones.Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersKinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengueAn adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell responseTesting of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacyRole of T-cell epitope-based vaccine in prophylactic and therapeutic applications.Immunologic hypo- or non-responder in natural dengue virus infectionA chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a.Developing a dengue vaccine: progress and future challenges.Production and testing of dengue virus strains suitable for human infection studies.Changing pattern of dengue virus serotypes circulating during 2008-2012 and reappearance of dengue serotype 3 may cause outbreak in Kolkata, India.Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.Dengue fever with hemorrhagic features in a special forces soldier.Study of anti-dengue NS1 antibody by western blot.The necessity and quandaries of dengue vaccine development.The dengue human challenge model: has the time come to accept this challenge?
P2860
Q24607960-B6C8AE63-B60D-4659-B7CE-79245EE1B5C8Q24616798-9C6B4921-8B28-4C29-8DC9-4C083C921913Q27469872-26339793-F506-4D83-8321-484633B168B8Q27469955-BE52C485-9379-4C2C-A1FA-86F5C7F4B3B7Q27480293-4449338F-B9F6-4113-9B04-9082F071AAC3Q27480386-6CAA3CC1-481F-4AAA-AB22-711D21462111Q27480391-57199A91-F22F-48EF-AFD5-4CF7EF2D8DD5Q27485093-F7AD4419-F572-4692-8D83-40675C77E809Q27486185-3968D5A6-7BC0-4EBC-A25D-098C8A1DAC40Q27490989-BAFBED06-7495-4F8B-8F34-6475ECCE74C2Q28476805-BA232C4A-D281-4D16-A0D2-326DDC948AF4Q35272502-61DD00E2-2FBE-4222-BB10-75820911E7A2Q35814043-9C3405E4-F835-4DF4-A459-988052AC1667Q36450864-693D1120-2860-4A67-B5CC-CFAF8376CC45Q36795668-69AB0880-3034-41D1-8C72-F3D24316E94DQ36922684-9D4E70C6-E8D2-400A-86E0-308AAA5F8F7DQ37336762-87B9DA60-C55A-4D63-805B-7BC7F2BBE706Q37360615-3D30B978-85C5-4C9B-8699-776A1A3456FDQ38201151-0AB54FA8-1587-4617-A86A-D8308726D6B2Q38990645-85BDC364-765A-491F-BBC5-980AF945831EQ39420042-2193BD78-40E0-4FE4-8588-695384F7172EQ40265040-BDF22C66-5D14-4BC3-A8C9-E07DC5F4A3F0Q40469197-1243DDA2-BD16-4E23-8780-208CBEB283D2Q40758115-8AE340F0-87A2-46E9-8758-F70421771BADQ42710655-EBF38814-DC13-4339-B3B8-DB7FC96F70E3Q42987133-08943F37-0AE3-4ACC-A4B7-672B6E8CCBDB
P2860
Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Virulence of a live dengue vir ...... r of dengue virus attenuation.
@en
type
label
Virulence of a live dengue vir ...... r of dengue virus attenuation.
@en
prefLabel
Virulence of a live dengue vir ...... r of dengue virus attenuation.
@en
P2093
P356
P1476
Virulence of a live dengue vir ...... r of dengue virus attenuation.
@en
P2093
Bancroft WH
Kraiselburd E
Meadors GF
P304
P356
10.1093/INFDIS/158.4.876
P407
P577
1988-10-01T00:00:00Z